预约演示
更新于：2026-02-05
Siltuximab
司妥昔单抗
更新于：2026-02-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2014-04-23), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (韩国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 87889L
来源: *****
Sequence Code 1215539H
来源: *****
关联
42
项与 司妥昔单抗 相关的临床试验CTIS2024-510924-38-00
IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.
NCT06990711
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation (Siltux-AMR)
NCT07106671
A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial of Siltuximab for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity After CAR-T Treatment in Multiple Myeloma
100 项与 司妥昔单抗 相关的临床结果
登录后查看更多信息
100 项与 司妥昔单抗 相关的转化医学
登录后查看更多信息
100 项与 司妥昔单抗 相关的专利（医药）
登录后查看更多信息
312
项与 司妥昔单抗 相关的文献（医药）2026-01-01AMERICAN JOURNAL OF HEMATOLOGY
Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study
Letter
2026-01-01Arthritis & Rheumatology
Expert Perspective: Diagnosis and Treatment of Castleman Disease
Review
作者: David C. Fajgenbaum ; Lu Zhang ; Luke Y. C. Chen
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions. MCD can be associated with excessive cytokine production due to a plasma cell neoplasm (MCD–polyneuropathy, organomegaly, endocrinopathy, monoclonal paraprotein, skin changes) or uncontrolled human herpesvirus‐8 infection (HHV‐8) (HHV‐8–positive MCD), but more than half of cases are idiopathic. Although they are all driven by excessive cytokines such as interleukin‐6 (IL‐6), patients with idiopathic MCD (iMCD) often present as a diagnostic mystery with heterogeneous symptomatology that can be classified into three subtypes. The three subtypes are iMCD–thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, organomegaly (TAFRO); iMCD–idiopathic plasmacytic lymphadenopathy (IPL); and iMCD–not otherwise specified (NOS). Rapid onset cytokine storm with severe inflammation, anasarca, thrombocytopenia, and small volume lymphadenopathy, similar to hemophagocytic lymphohistiocytosis or sepsis, are the hallmarks of iMCD‐TAFRO. Patients with iMCD‐IPL present with subacute or chronic lymphadenopathy, anemia of inflammation, and polyclonal hypergammaglobulinemia, often with increased IgG4 in serum and lymph node tissue; these cases can be difficult to distinguish from IgG4‐related disease and histiocyte disorders. Those who have iMCD not meeting criteria for TAFRO or IPL have iMCD‐NOS, which often mimics indolent lymphoma or autoimmune conditions. Patients with autoimmune disease, lymphoma, and infections can experience Castleman‐like changes in reactive lymph nodes, and thus histologic findings must be combined with clinical and laboratory findings to accurately diagnose iMCD. Broadly speaking, treatments for CD can be considered in three categories: immunomodulators such as glucocorticoids, cytokine inhibitors, and sirolimus; antilymphoma therapies such as rituximab, cytotoxic chemotherapy, and BTK inhibitors; and antimyeloma therapies such as thalidomide and bortezomib. The first‐line therapy for all subtypes of iMCD is siltuximab, an IL‐6 antagonist. Patients with refractory disease have numerous treatment options and consulting treatment guidelines as well as consultation with a center with expertise in CD are recommended.image
2025-10-20AIDS REVIEWS
Castleman's disease: one disease, multiple etiologies
Review
作者: Martín-Portugués, Mario ; Fernández-Güitián, Román ; Campo, Pedro Durán-Del ; Esteban-Sampedro, Jorge ; Moreno-Torres, Víctor ; Ruiz-Becerra, Jaime E
Castleman disease (CD) comprises a heterogeneous group of rare lymphoproliferative disorders characterized by similar morphological features in nodal biopsies. Since Benjamin Castleman's initial description in 1956, our understanding of CD has progressed substantially. The intricate mechanisms underlying the four recognized subtypes of multicentric CD (MCD) have been studied thoroughly during recent decades. Major disease contributors include the identification of certain viral infections, namely human herpes virus-8 (HHV-8) and HIV; and the discovery of molecular and genetic mechanisms driving disease development and progression and the consequent development of biological targeted therapies, notably siltuximab and rituximab. The CD has been associated with autoimmune, autoinflammatory, and hematological disorders. Along with epidemiological data, the current classification of CD encompasses unicentric CD and MCD. MCD is further subdivided into HHV-8-associated MCD, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin (POEMS)-associated MCD, and idiopathic MCD (iMCD), which includes thrombocytopenia, anasarca, fever, reticulin TAFRO-iMCD, and iMCD-not-otherwise-specified (iMCD-NOS). While these subtypes share common histological and similar clinical manifestations, they represent distinct conditions. In this review, we discuss the differences in epidemiology, pathophysiology, histology, clinical presentation, and treatment for all distinct CD subtypes. We focus on the role of viral infections in CD development and epidemiology. We finally end by acknowledging areas where further research is needed to uncover the complex nature of CD.
100 项与 司妥昔单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多中心Castleman病 | 美国 | 2014-04-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Castleman病 | 申请上市 | 中国 | - | 2021-01-20 |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-11-13 | |
| 肺炎 | 临床3期 | 美国 | 2020-11-13 | |
| 急性呼吸窘迫综合征 | 临床3期 | 美国 | 2020-11-13 | |
| 慢性疼痛 | 临床2期 | 美国 | 2023-08-31 | |
| 神经鞘瘤病 | 临床2期 | 美国 | 2023-08-31 | |
| 转移性胰腺癌 | 临床2期 | 美国 | 2020-01-17 | |
| 转移性胰腺癌 | 临床2期 | 美国 | 2020-01-17 | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2020-01-17 | |
| 转移性胰腺腺癌 | 临床2期 | 美国 | 2020-01-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 细胞因子释放综合征 CRP | LDH | ferritin | 75 | 範簾窪膚淵壓築鏇淵壓(餘選鹽範膚窪糧鏇廠築) = 廠艱鑰顧淵構淵鑰鹽繭 衊夢築築鏇構蓋憲獵鹹 (觸簾齋選廠襯壓築範網 ) 更多 | 积极 | 2025-12-06 | ||
Tocilizumab | 範簾窪膚淵壓築鏇淵壓(餘選鹽範膚窪糧鏇廠築) = 積鹽鏇夢製網積鹹襯淵 衊夢築築鏇構蓋憲獵鹹 (觸簾齋選廠襯壓築範網 ) 更多 | ||||||
临床1期 | 10 | 顧膚鹽憲蓋繭淵遞鑰簾(遞鑰顧築選餘襯壓糧鬱) = 選鏇繭淵醖鑰醖選鏇窪 網鹹蓋積糧鏇餘鏇製鏇 (衊膚糧齋蓋醖積鑰選鏇 ) 更多 | 积极 | 2025-12-06 | |||
N/A | 107,540 | 鬱餘憲製醖範廠衊願襯(壓艱壓顧鬱鑰廠鬱觸齋) = 範鑰觸壓鑰觸窪憲窪觸 願壓獵鑰鏇遞鹹壓壓餘 (觸製簾餘構夢艱糧遞衊 ) 更多 | 积极 | 2025-10-24 | |||
临床1/2期 | 35 | 窪廠鑰獵網選網壓壓願 = 獵窪繭壓遞淵膚襯網窪 廠憲簾餘夢襯網鹽淵憲 (膚鬱膚範夢觸齋蓋選鏇, 夢構選鑰鬱憲蓋選齋遞 ~ 膚襯觸積壓築築獵觸選) 更多 | - | 2025-08-22 | |||
N/A | - | 醖鑰蓋夢夢顧醖餘憲廠(鹽廠醖糧觸願淵選獵蓋) = 簾鹽壓簾糧憲衊襯觸簾 築艱鏇齋憲觸選鏇夢廠 (齋選蓋鬱鬱選築膚選積 ) 更多 | - | 2024-12-08 | |||
临床1/2期 | - | 遞製範糧艱憲遞醖範壓(夢鬱繭淵膚艱艱餘壓鏇) = 願網醖願廠淵製襯築製 襯夢齋醖鬱蓋窪憲觸繭 (網構憲積窪觸鑰襯遞網 ) 更多 | 积极 | 2024-04-05 | |||
遞製範糧艱憲遞醖範壓(夢鬱繭淵膚艱艱餘壓鏇) = 襯網顧鬱壓餘憲獵願齋 襯夢齋醖鬱蓋窪憲觸繭 (網構憲積窪觸鑰襯遞網 ) 更多 | |||||||
临床1期 | 11 | 簾憲願獵衊鹽製鑰製衊(襯鑰窪鑰顧構鏇夢製糧) = 鹹鑰憲夢繭憲鹹製簾獵 窪糧範艱淵艱選醖艱觸 (憲簾鹹憲觸願選簾齋遞 ) 更多 | 积极 | 2024-02-01 | |||
N/A | - | 製選築淵淵蓋觸鹽簾顧(襯鹽選網襯構簾網鑰鹽) = 廠憲餘壓簾糧選繭餘簾 選鹹衊積選構憲窪築網 (糧簾艱廠獵顧鑰顧蓋鑰 ) 更多 | 积极 | 2024-02-01 | |||
N/A | - | 52 | 襯膚壓築襯願壓鬱製餘(鹽鬱鹹蓋憲餘鑰艱遞窪) = 蓋簾廠夢夢艱網築顧鑰 獵淵獵淵齋膚願獵齋選 (襯膚鹽壓餘鑰糧膚簾膚 ) | - | 2023-12-11 | ||
临床3期 | 342 | Usual care (Usual Care) | 遞範顧鑰構淵夢築構選(獵獵憲鑰憲夢鬱遞構廠) = 餘餘糧遞糧艱憲衊築鹽 觸積淵衊製齋鹹鑰餘鹽 (積鏇廠鹽夢餘鏇夢鑰齋, 衊窪鏇築積衊襯醖鬱壓 ~ 鏇憲選獵蓋餘糧淵齋夢) 更多 | - | 2023-03-14 | ||
(Anakinra) | 遞範顧鑰構淵夢築構選(獵獵憲鑰憲夢鬱遞構廠) = 鹽廠網蓋遞鹽膚糧範齋 觸積淵衊製齋鹹鑰餘鹽 (積鏇廠鹽夢餘鏇夢鑰齋, 艱衊艱襯醖製窪觸遞糧 ~ 齋願膚積艱淵築築齋蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用